A carregar...
Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
Ozanimod is a novel, selective, oral sphingosine‐1‐phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease. This randomized, double‐blind, placebo‐controlled, positive‐controlled, parallel‐group thorough QT study characterized the effects of ozanim...
Na minha lista:
| Publicado no: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5901414/ https://ncbi.nlm.nih.gov/pubmed/28783871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.383 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|